Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis

Abstract Introduction Some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic keratoconjunctivitis (AKC) with/without giant papillae. We hypothesized that different factors are involved in the severity of ACD and AD...

Full description

Saved in:
Bibliographic Details
Main Authors: Mayumi Ueta, Hiromi Nishigaki, Seitaro Komai, Chie Sotozono, Shigeru Kinoshita
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Immunity, Inflammation and Disease
Subjects:
Online Access:https://doi.org/10.1002/iid3.536
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849708652648202240
author Mayumi Ueta
Hiromi Nishigaki
Seitaro Komai
Chie Sotozono
Shigeru Kinoshita
author_facet Mayumi Ueta
Hiromi Nishigaki
Seitaro Komai
Chie Sotozono
Shigeru Kinoshita
author_sort Mayumi Ueta
collection DOAJ
description Abstract Introduction Some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic keratoconjunctivitis (AKC) with/without giant papillae. We hypothesized that different factors are involved in the severity of ACD and AD. Recently we reported that hsa‐miR‐628‐3p could affect the balance of innate immunity by suppressing pathogen‐associated molecular patterns such as toll‐like receptor 3 (TLR3), RIG‐I, and MDA‐5. We also reported that TLR3 positively regulates ocular surface‐ and skin inflammation such as contact dermatitis and AD. Here we compared the plasma level of miR‐628‐3p in AD patients with severe AKC with giant papillae and/or shield ulcers, with the level in healthy controls and AD patient without AKC or with very mild AKC. Methods We used the plasma from 32 AD patients with severe AKC, from 40 healthy controls, and from 23 AD patient without AKC or with very mild AKC without giant papillae nor shield ulcers. Quantitative microRNA PCR assays were used to measure their plasma level of miR‐628‐3p. Results We found that plasma miR‐628‐3p was upregulated in AD with severe AKC, but not in severe AD without severe AKC, nor in our healthy controls. Conclusion Our new findings suggest that the plasma miR‐628‐3p level may represent a marker to predict the presence of severe AKC in AD patients.
format Article
id doaj-art-e52763867f10454698cf3ce38c100299
institution DOAJ
issn 2050-4527
language English
publishDate 2021-12-01
publisher Wiley
record_format Article
series Immunity, Inflammation and Disease
spelling doaj-art-e52763867f10454698cf3ce38c1002992025-08-20T03:15:35ZengWileyImmunity, Inflammation and Disease2050-45272021-12-01941815181910.1002/iid3.536Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitisMayumi Ueta0Hiromi Nishigaki1Seitaro Komai2Chie Sotozono3Shigeru Kinoshita4Department of Ophthalmology Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Ophthalmology Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Ophthalmology Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Ophthalmology Kyoto Prefectural University of Medicine Kyoto JapanDepartment of Frontier Medical Science and Technology for Ophthalmology Kyoto Prefectural University of Medicine Kyoto JapanAbstract Introduction Some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic keratoconjunctivitis (AKC) with/without giant papillae. We hypothesized that different factors are involved in the severity of ACD and AD. Recently we reported that hsa‐miR‐628‐3p could affect the balance of innate immunity by suppressing pathogen‐associated molecular patterns such as toll‐like receptor 3 (TLR3), RIG‐I, and MDA‐5. We also reported that TLR3 positively regulates ocular surface‐ and skin inflammation such as contact dermatitis and AD. Here we compared the plasma level of miR‐628‐3p in AD patients with severe AKC with giant papillae and/or shield ulcers, with the level in healthy controls and AD patient without AKC or with very mild AKC. Methods We used the plasma from 32 AD patients with severe AKC, from 40 healthy controls, and from 23 AD patient without AKC or with very mild AKC without giant papillae nor shield ulcers. Quantitative microRNA PCR assays were used to measure their plasma level of miR‐628‐3p. Results We found that plasma miR‐628‐3p was upregulated in AD with severe AKC, but not in severe AD without severe AKC, nor in our healthy controls. Conclusion Our new findings suggest that the plasma miR‐628‐3p level may represent a marker to predict the presence of severe AKC in AD patients.https://doi.org/10.1002/iid3.536allergy processesepigenetics processeshumanmucosa tissues
spellingShingle Mayumi Ueta
Hiromi Nishigaki
Seitaro Komai
Chie Sotozono
Shigeru Kinoshita
Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
Immunity, Inflammation and Disease
allergy processes
epigenetics processes
human
mucosa tissues
title Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
title_full Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
title_fullStr Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
title_full_unstemmed Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
title_short Difference in the plasma level of miR‐628‐3p in atopic dermatitis patients with/without atopic keratoconjunctivitis
title_sort difference in the plasma level of mir 628 3p in atopic dermatitis patients with without atopic keratoconjunctivitis
topic allergy processes
epigenetics processes
human
mucosa tissues
url https://doi.org/10.1002/iid3.536
work_keys_str_mv AT mayumiueta differenceintheplasmalevelofmir6283pinatopicdermatitispatientswithwithoutatopickeratoconjunctivitis
AT hirominishigaki differenceintheplasmalevelofmir6283pinatopicdermatitispatientswithwithoutatopickeratoconjunctivitis
AT seitarokomai differenceintheplasmalevelofmir6283pinatopicdermatitispatientswithwithoutatopickeratoconjunctivitis
AT chiesotozono differenceintheplasmalevelofmir6283pinatopicdermatitispatientswithwithoutatopickeratoconjunctivitis
AT shigerukinoshita differenceintheplasmalevelofmir6283pinatopicdermatitispatientswithwithoutatopickeratoconjunctivitis